Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Darunavir Viatris (previously Darunavir Mylan)
Darunavir Viatris 400 mg film-coated tablets Darunavir Viatris 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 57
HOS-134621 · Präparat HOS-097580
Amitriptyline Concomitant use of boosted Clinical monitoring is recommended
Desipramine darunavir and these antidepressants when co-administering boosted
Imipramine may increase concentrations of the darunavir with these antidepressants
Nortriptyline antidepressant. and a dose adjustment of the
Trazodone (CYP2D6 and/or CYP3A antidepressant may be needed.
inhibition)
ANTI-DIABETICS
Metformin Not studied. Based on theoretical Careful patient monitoring and dose
considerations darunavir co- adjustment of metformin is
administered with cobicistat is recommended in patients who are
expected to increase metformin taking darunavir co-administered
plasma concentrations. with cobicistat.
(MATE1 inhibition) (not applicable for darunavir co-
administered with ritonavir)
ANTIEMETICS
Domperidone Not studied. Co-administration of domperidone
with boosted darunavir is
contraindicated.
ANTIFUNGALS
Voriconazole Not studied. Ritonavir may Voriconazole should not be
decrease plasma concentrations of combined with boosted darunavir
voriconazole. unless an assessment of the
(induction of CYP450 enzymes) benefit/risk ratio justifies the use of
voriconazole.
Concentrations of voriconazole may
increase or decrease when co-
administered with darunavir co-
administered with cobicistat.
(inhibition of CYP450 enzymes)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nortriptyline (HOS-086245) amitriptyline (HOS-085911) desipramine (HOS-086249) imipramine (HOS-085907) cobicistat (HOS-088111) domperidone (HOS-114656) voriconazole (HOS-084524) trazodone (HOS-086251) ritonavir (HOS-084521) metformin (HOS-091032)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T12:32:00Z · SHA-256 50f4771a683f17214737463c6df88a158b1e699bbb9916413602e547e369e804 · Passage 27799a8d8e538324cfbdb7d65793ead639dfa85c24213e1e87ce9b2c7b4b1622 · Zeichen 37685–39889 im Abschnitt
Wechselwirkungen · Symtuza
Symtuza 800 mg/150 mg/200 mg/10 mg film-coated tablets Symtuza 675 mg/150 mg/200 mg/10 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 12
HOS-138484 · Präparat HOS-098200
Based on theoretical considerations
Amitriptyline DRV/COBI is expected to increase
Desipramine these anti-depressant plasma
Imipramine concentrations.
Nortriptyline (CYP2D6 and/or CYP3A
Trazodone inhibition)
ANTI-DIABETICS
Metformin Based on theoretical considerations Careful clinical monitoring and
DRV/COBI is expected to increase dose adjustment of metformin is
metformin plasma concentrations. recommended in patients who are
(MATE1 inhibition) taking Symtuza.
ANTIEMETICS
Domperidone Not studied. Co-administration of
domperidone with Symtuza is
contraindicated.
ANTIFUNGALS
Clotrimazole Based on theoretical considerations Caution is warranted and clinical
Fluconazole DRV/COBI is expected to increase monitoring is recommended.
Itraconazole these antifungal plasma When co-administration is
concentrations, and darunavir, required, the daily dose of
Isavuconazole cobicistat and/or tenofovir itraconazole should not exceed
Posaconazole alafenamide plasma concentrations 200 mg.
may be increased by the
antifungals.
(CYP3A and/or P-gp inhibition)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) isavuconazole (HOS-085186) nortriptyline (HOS-086245) amitriptyline (HOS-085911) desipramine (HOS-086249) imipramine (HOS-085907) clotrimazole (HOS-090574) domperidone (HOS-114656) itraconazole (HOS-084516) trazodone (HOS-086251) fluconazole (HOS-087945) posaconazole (HOS-085622) metformin (HOS-091032)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-16T11:21:00Z · SHA-256 542f840b29cc7afaff9940b20511550e8d35031b33d95efd774fd49f70f7819d · Passage 061584a4f2d3686461b02951b37d12cd2e74b66b2c1221794b17ed1d0cb7ecd1 · Zeichen 15577–17097 im Abschnitt
Wechselwirkungen · Slenyto
Slenyto 1 mg prolonged-release tablets Slenyto 5 mg prolonged-release tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-138606 · Präparat HOS-098224
Thioridazine and imipramine
Melatonin has been co-administered in studies with thioridazine and imipramine, active substances
which affect the central nervous system. No clinically significant pharmacokinetic interactions were
found in each case. However, melatonin co-administration resulted in increased feelings of tranquility
and difficulty in performing tasks compared to imipramine alone, and increased feelings of “muzzy-
headedness” compared to thioridazine alone. Combination with thioridazine and imipramine should
be avoided.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): imipramine (HOS-085907) thioridazine (HOS-086281)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-10T15:35:00Z · SHA-256 17494391b1b166184a1056469270f628e4597dda5631ec4cd470a78d59405d08 · Passage ea72eb5fcec4b899b9c01d426d7377c62f60ecadbe11060f104d2d7c40280a94 · Zeichen 1452–1988 im Abschnitt
Wechselwirkungen · Ozawade
Ozawade 4.5 mg film-coated tablets Ozawade 18 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-144403 · Präparat HOS-099178
Tri or tetracyclic antidepressants with anti-histaminic H1-receptor properties (e.g. imipramine,
clomipramine, mirtazapine) may impair the efficacy of pitolisant because they may decrease the effect
of endogenous histamine released in brain by the treatment and alternative should be used.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): imipramine (HOS-085907) histamine (HOS-088516) clomipramine (HOS-085906) mirtazapine (HOS-144406)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-06T11:36:00Z · SHA-256 6132349ff4302f19688e606b853696608a2e68d699ec2c7f66e494671825abac · Passage cf24da198480fcff760a8fe4894857639f6fa1284b991bed861509a81e728e42 · Zeichen 47–336 im Abschnitt
Wechselwirkungen · Voranigo
Voranigo 10 mg film-coated tablets Voranigo 40 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-152390 · Präparat HOS-100749
Co-administration of vorasidenib with CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP3A4 substrates
with narrow therapeutic index (including, but not limited to, amitriptyline, alfentanil, carbamazepine,
ciclosporin, dosulepin, everolimus, fentanyl, fosphenytoin, ifosfamide, imipramine, phenobarbital,
phenytoin, pimozide, quinidine, sirolimus, tacrolimus, tamoxifen, trimipramine, valproic acid, and
warfarin) may decrease the plasma concentrations of these medicinal products. Concomitant use of
substrates of these enzymes with narrow therapeutic index should be avoided in patients taking
vorasidenib.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fosphenytoin (HOS-110222) alfentanil (HOS-109375) amitriptyline (HOS-085911) phenobarbital (HOS-085617) valproic acid (HOS-088515) trimipramine (HOS-152398) carbamazepine (HOS-085618) imipramine (HOS-085907) tamoxifen (HOS-088380) quinidine (HOS-085593) ifosfamide (HOS-091529) tacrolimus (HOS-085202) pimozide (HOS-085600) everolimus (HOS-086310) sirolimus (HOS-085172) fentanyl (HOS-086196) phenytoin (HOS-084531) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-27T16:33:00Z · SHA-256 2232f34043666605447d216a0f9efae95496605e48741a446bf6879643808d62 · Passage 3d550b9ad3b19c779ebfbf7d68a0ec9fc3073bab44b0453f3efc8e4f9e0983a9 · Zeichen 1607–2205 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.